Panelists at the Academy of Managed Care Pharmacy (AMCP) Nexus meeting chronicled the current state of the US biosimilar market, including current policies impacting the market, recent regulatory decisions, and the developing arguments around requirements for clinical efficacy studies.
As the US biosimilars industry continues to grow and more products enter the market, a better understanding of the development process, regulatory framework, and policy landscape can assist pharmacists in propelling the industry forward, according to panelists at the AMCP Nexus meeting.
Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist and pharmaceutical formulary manager at Mayo Clinic, began the session with an overview of the market, emphasizing the significant adoption growth since 2020, especially for products in the medical benefit (bevacizumab and filgrastim biosimilars). She also highlighted the current biosimilar pipeline, including several eculizumab, aflibercept, denosumab, and ustekinumab products as well as the recent FDA approval of the first tocilizumab biosimilar.
Jensen mentioned Mayo Clinic’s success with implementing biosimilars into regular practice, saving $23.1 million and $10.8 million in the program’s first and second years, respectively. She said that collaborating with payers, optimizing electronic health records, and communicating with prescribers in a clear and timely manner about upcoming changes are important strategies for health systems to take to ensure successful biosimilar implementation.
The outline of the regulatory framework for biosimilars was presented by Juwaria Waheed, MD, Scientific Reviewer for the Office of Therapeutic Biologics and Biosimilars. Waheed explained that the comparative analytical assessment comparing a biosimilar to its reference agent is the foundation of the biosimilar approval pathway. However, clinical studies play a small role in approval decisions because they are intended to demonstrate comparable efficacy and safety rather than establish new evidence.
“It is not a sensitive enough endpoint to tell you if there were actual differences in the product, we wouldn't be able to tell with that endpoint. So, it's a limited endpoint. It works great works excellent in de novo programs as well as for comparative efficacy. But if there were truly differences at an analytical level [between the products], it would be very hard to tell with these clinical studies.”
Waheed said that the FDA is working to further decrease reliance on clinical studies by leveraging analytical data and gaining more experience with biosimilars approved so far.
In addition to clinical efficacy trials, switching studies to obtain interchangeability are contentious. Jensen noted that study design is very important when evaluating whether transitioning from a reference product to a biosimilar and vice versa is safe and effective to do, quoting a study that found that cross switches that occurred within a 6 month or less period could hamper the ability to accurately trace immune responses.
As part of BsUFA III, the FDA funds "demonstration projects" to identify alternatives to comparative clinical immunogenicity assessments and leveraging real-world data as a means to enhance regulatory decision-making and facilitate science-based recommendations for biosimilar development.
Click to enlarge.
Kimberly Maxfield, PhD, a pharmacologist for the FDA, went over biosimilar marketplace trends and policy considerations, such as the impact of the third authorization of the Biosimilar User Fee Act (BsUFA III), which increases the FDA’s funding for projects designed to enhance regulatory decision-making and facilitating science-based recommendations in areas foundational to biosimilar development. BsUFA III extends from October 1, 2022 to September 30, 2027. (Figure)
The FDA has created a pilot program as part of BsUFA III, which will help find alternatives to reducing the size of clinical trials and increase reliance on analytical data through research projects. The program has funded several projects looking at analytical similarity, developing alternatives to comparative clinical immunogenicity assessments, and leveraging real-world data.
Maxfield concluded, “A lot of this program is defined by our stakeholders…We've tried to do as much stakeholder engagement as absolutely possible [with] actual user fee negotiations, public comment periods, and [including] broader non-FDA reviewers into the grant review cycle…. And we're still looking at other methods to make sure that the smaller developers, the less experienced developers who have different questions than the more experienced ones, are having their voices is be heard.”
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.
2 Commerce Drive
Cranbury, NJ 08512